Allarity Therapeutics, Inc.
ALLRNASDAQHealthcare● Active
$1.58
$-0.03(-1.86%)
Market Cap$25138944
P/E Ratio—
52W High$2.35
52W Low$0.769
Allarity Therapeutics, Inc. (ALLR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALLR · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.32M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.12M | $0.11M |
| Gross Profit | $0.32M | $0.00M | $0.00M | ($0.12M) | ($0.11M) |
| Gross Margin %(computed) | 100.00% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $6.60M | $6.10M | $7.10M | $6.93M | $14.20M |
| G&A Expenses | $6.32M | $11.44M | $10.03M | $9.96M | $12.36M |
| Total Operating Expenses | $12.93M | $27.24M | $17.13M | $34.46M | $26.56M |
| Operating Income | ($12.61M) | ($27.24M) | ($17.13M) | ($34.46M) | ($26.56M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.80M | $0.53M | $0.02M | $0.03M | $0.00M |
| Interest Expense | $0.18M | $0.65M | $0.50M | $0.22M | $0.64M |
| Income Before Tax | ($11.23M) | ($24.90M) | ($11.82M) | ($17.58M) | ($26.52M) |
| Income Tax Expense | $0.00M | ($0.38M) | $0.08M | ($1.52M) | $0.13M |
| Net Income | ($11.23M) | ($24.52M) | ($11.90M) | ($16.06M) | ($26.65M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.78 | $-15.79 | $-6031.31 | $-31799.09 | $-79074.18 |
| Wtd Avg Shares | 14.38M | 1.61M | 3.32M | 0.01M | 0.01M |
| EBITDA | ($11.05M) | ($24.23M) | ($11.28M) | ($17.30M) | ($25.77M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Allarity Therapeutics, Inc. data
About Allarity Therapeutics, Inc. (ALLR) Income Statement
Allarity Therapeutics, Inc. (ALLR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ALLR reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.01B) — a net profit margin of -3509.69%.
Frequently asked questions
ALLR · 4 questionsAllarity Therapeutics, Inc. (ALLR) reported revenue of $0.00B for 2025, up —% year-over-year.
ALLR revenueALLR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09